Trial Profile
Randomized control study investigating the efficacy of prophylactic administration of nafomostat mesilate in reducing the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Feb 2016
Price :
$35
*
At a glance
- Drugs Nafamostat (Primary)
- Indications Pancreatic disorders; Pancreatitis
- Focus Therapeutic Use
- 08 Feb 2016 New trial record